Lead Product(s) : LUT-014
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Columbus Venture Partners
Deal Size : $30.0 million
Deal Type : Financing
Lutris Secures $30M for Biopharma Advancing Anti-Cancer Drug Effectiveness
Details : The financing aims to advance the clinical development of the company’s investigational product LUT014, which is being evaluated for the treatment of EGFRI-Induced Acneiform Rash.
Product Name : LUT014
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
January 28, 2025
Lead Product(s) : LUT-014
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Columbus Venture Partners
Deal Size : $30.0 million
Deal Type : Financing
Lead Product(s) : LUT-014
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lutris Completes Enrollment in Phase 2 LUT014 Trial for Acneiform Rash
Details : LUT014 is a novel BRAF inhibitor, small molecule drug which is applied topically on the skin. It is being evaluated for the treatment of EGFRI-Induced Acneiform Rash.
Product Name : LUT-014
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 15, 2024
Lead Product(s) : LUT-014
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : LUT-014
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lutris Pharma Secures FDA ODD for LUT014 for EGFRI-Induced Acneiform Rash
Details : LUT014 is a novel B-Raf inhibitor, small molecule drug which is applied topically on the skin. It is being evaluated for the treatment of EGFRI-Induced Acneiform Rash.
Product Name : LUT-014
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 28, 2024
Lead Product(s) : LUT-014
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : BX001
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
BiomX Reports Topline Results of Phase 2 Cosmetic Acne Study
Details : BX001 is a topical gel formulation of a cocktail of naturally-occurring phage designed to improve the appearance of acne-prone skin by targeting Cutibacterium acnes (C. acnes), which are bacteria implicated in the pathophysiology of acne vulgaris.
Product Name : BX001
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 18, 2021
Lead Product(s) : BX001
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : LUT-014
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ALLO-501A, a next-generation anti-CD19 AlloCAR T , eliminates the rituximab recognition domains in ALLO-501, which could allow for use in a broader patient population, including NHL patients with recent rituximab exposure.
Product Name : LUT-014
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 28, 2021
Lead Product(s) : LUT-014
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : LUT-014
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lutris Pharma Doses First U.S. Patients in Phase 2 Trial of LUT014
Details : The trial will evaluate the efficacy and safety of two strengths of LUT014 Gel, 0.03% or 0.10%, applied once daily for 4 weeks, compared to placebo, in patients with mCRC who develop Grade 2 EGFR inhibitor-induced acneiform lesions, with a 4-week follow ...
Product Name : LUT-014
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 08, 2021
Lead Product(s) : LUT-014
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable